Novo Nordisk plans to cut price of Ozempic as generics hit market

Novo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmakers launched cheaper generic versions of semaglutide. Industry sources suggest Novo's revised price will be competitive. This strategy aims to capture a larger market share against aggressive pricing from Indian companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/raAu7Yq
via IFTTT